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Iron deficiencya b s t r a c t
Haemophilia-A is an X-linked recessive bleeding disorder characterized by deficiency of FVIII. Although
severity of haemophilia is largely determined by the extent to which different mutations abolish FVIII
production, the overall phenotypic variations among haemophiliacs is determined by a combination of
several other factors, which range from general to tropical factors on the one hand, and from genetic
to immunologic and infective factors on the other hand. Determinants and modifiers of haemophilic
bleeding phenotypes are important predictors of prognosis. However, tropical determinants of haemo-
philic bleeding phenotypes are virtually ignored because majority of haemophilia research originated
from developed non-tropical countries. The aim of this paper is to present a balanced review of the hae-
mophilic bleeding phenotypes from general and tropical perspectives. Hence, we present a concisely
updated comprehensive review of the pathophysiologic and clinical significance of general vis-à-vis trop-
ical determinants and modifiers of haemophilic bleeding phenotypes from genetic, immunologic and
infective perspectives. Understanding of general phenotypic determinants such as FVIII gene mutations,
immunological (inhibitors) and infective (e.g. hepatitis and HIV) complications, classical thrombophilias
(e.g. FV-Leiden) and non-classical thrombophilias (e.g. non-O blood groups) will throw more light into
the mechanisms by which some tropical prothrombotic gene mutations (such as sickle b-globin gene)
and certain chronic tropical pro-haemorrhagic parasitic infections (such as urinary and gastrointestinal
helminthiasis) may modify frequency, intensity and pattern of bleeding among haemophiliacs in the
tropics. The clinical significance of iron deficiency within the context of helminthiasis and haemophilia
is also reviewed. More research is needed to determine the precise effect of non-classical thrombophilias
such as sickling disorders and ABO blood groups on haemophilic bleeding phenotypes. Meanwhile,
tropical healthcare workers should incorporate regular screening and treatment for common pro-
haemorrhagic parasitic diseases and iron deficiency into standard of care for management of
haemophilia.
 2017 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
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Haemophilia-A is an X-linked recessive disorder characterized
by deficiency of clotting factor VIII (FVIII) [1]. Inadequate FVIII
levels result in insufficient formation of the intrinsic tenase com-
plex (FIXa, FVIIIa, Ca2+ and Phospholipids) which subsequently
leads to reduced generation of thrombin with impaired fibrin
deposition and clot formation [1]. However, the bleeding disorder
in haemophilia-A is not merely a reflection of reduced clot forma-
tion due to low FVIII activity. The pathophysiology of the bleeding
diathesis in haemophilia-A is in fact the result of an interplay
between a defective procoagulant process and a deregulated fibri-
nolytic process. Bleeding is triggered either by identifiable trauma
(referred to as trauma-induced bleeding) or unidentifiable trauma
(referred to as spontaneous bleeding), noting that these so-called
‘spontaneous bleeds’ are usually caused by some form of trivial
unrecognizable trauma [2]. As expected from physiological per-
spective, the local tissue damage and vascular endothelial injury
at the site of bleeding would simultaneously activate the intrinsic
pathway (via contact activation) [3], the extrinsic pathway (via
release of tissue factor) [3] and the fibrinolytic pathway (via
release of tissue plasminogen activator) [4]. Moreover, the activity
of fibrinolytic pathway, which is triggered by contact-activated
FXIIa [5] as well as the tissue plasminogen activator [4], proceeds
normally. In contradistinction to the fibrinolytic pathway, the pro-
coagulant pathways are hindered by the summation of a series of
haemostatic anomalies, which is initiated by the low FVIII activity
followed by reduced initial thrombin generation via the intrinsic
pathway [6]. The next haemostatic anomaly is the failure of the
extrinsic pathway to adequately compensate for the insufficient
thrombin generation by intrinsic pathway [6]. The inadequate
compensation by the extrinsic pathway leads to the absence of suf-
ficient burst of thrombin, which is necessary for activation of
thrombin activable fibrinolysis inhibitor (TAFI) [6]. This persistent
lack of sufficient thrombin burst ultimately leads to sub-optimal
activation of TAFI with a resultant defective down regulation of fib-
rinolysis [6]. Therefore, the haemostatic failure in haemophilia-A
can be viewed as a vicious combination of poor fibrin clot forma-
tion on the one hand and an up-regulated fibrinolysis on the other
hand [6]. Moreover, the production of tissue factor pathway inhibi-
tor (TFPI) by synovial cells and chondrocytes leads to localized
intra-articular attenuation of the extrinsic pathway, which conse-
quently aggravates bleeding tendency within the joints [7]. Other
local aggravators of haemophilic bleeding include plasminogen
activators produced by the kidneys [8] and the prostate [9], which
aggravate urinary tract bleeding; and the fibrinolytic effect of sal-
iva, which aggravate bleeding within the oral cavity [10].
Although the overall severity of haemophilia is largely deter-
mined by the extent to which different mutations abolish func-
tional FVIII production, the overall phenotypic variations among
haemophiliacs is determined by additional confounding effects of
several other factors, which range from general to tropical factors
on one hand, and from genetic to immunologic and infective fac-
tors on the other hand. Determinants and modifiers of haemophilic
bleeding phenotypes are important predictors of bleeding rates
and clotting factor consumption, both of which are vital indicesin the clinical process of individual patient prognostication. Hence,
a thorough understanding and identification of these determinants
and modifiers are paramount for clinicians and other medical
personnel that are involved in the management of haemophilia.
However, tropical determinants of haemophilic bleeding pheno-
types are virtually ignored in the literature because the majority
of haemophilia research originated from developed non-tropical
countries. Because of the high prevalence of poverty, malnutrition
and infectious diseases in tropical countries, haemophiliacs living
in the tropics face peculiar challenges that are not present in the
developed regions of the world. Therefore, the aimed of this paper
is to present a balanced review of the haemophilic bleeding pheno-
types from general and tropical perspectives in order to highlight
the peculiarities of the tropical haemophiliacs. In this paper
we present a concisely updated comprehensive review of the
pathophysiologic and clinical significance of general vis-à-vis
tropical determinants and modifiers of bleeding phenotypes in
haemophilia-A from genetic, immunologic and infective perspec-
tives. The clinical significance of iron deficiency and its treatment
within the context of haemophilia is also reviewed.
2. General determinants and modifiers of haemophilic bleeding
phenotypes
Several factors are known to be important determinants and
modifiers of bleeding phenotypes of patients with haemophilia-A.
These factors include FVIII gene mutations and inhibitors, as well
as classical and non-classical thrombophilic conditions as outlined
in Table 1.
2.1. FVIII gene mutation
The severity of haemophilia is largely determined by the extent
to which different mutations abolish functional FVIII production.
The clinical severity of the disease and bleeding rates significantly
correlate with residual FVIII levels, which is classified as severe
(FVIII level <1%), moderate (FVIII level 1–5%) or mild (FVIII level
6–40%) [11]. Severe haemophilia, which is characterized by high
bleeding rates and frequent occurrence of apparently spontaneous
bleeding episodes, is typically associated with the null mutations
due to inversions, insertions, deletions, non-sense and mis-sense
mutations [11]. Whereas mild and moderate haemophilia, charac-
terized by lower rates of bleeding that is usually provoked by rec-
ognizable traumatic events, are usually associated with non-null
mutations due to less severe forms of mis-sense, single-
nucleotide deletions or splicing error mutations [11]. There is a
direct correlation between disease severity, bleeding rate and the
risk of iron deficiency among haemophiliacs [12]. A previous study
from Nigeria revealed that in comparison with non-severe
haemophiliacs, severe haemophiliacs had higher frequency and
relative risk of iron deficiency, a finding that was attributable to
the higher bleeding rates among severe haemophiliacs [12]. There
is no doubt that the FVIII gene mutation is the most important
determinant of disease severity and bleeding phenotype in
patients with haemophilia-A [11]. However, the phenotypic
heterogeneity of haemophilia-A is multi-factorial, which includes
Table 2
Risk Factors for FVIII Inhibitors Among Patients with Haemophilia-A.
Genetic risk factors
Type of FVIII Gene Mutation
Ethnic and Racial Mismatch
FVIII Haplotype Variation
Family History of Inhibitor in Siblings
Inheritance of Non-O Blood Group
Non-genetic risk factors
Non-Genetic Immune Modulators
(a) Infections and Vaccinations
(b) Accidental and Surgical Trauma
Age at onset of FVIII Therapy/Prophylaxis
Modality of FVIII administration: Continuous Infusions
Intensity of FVIII Therapy/Prophylaxis
Type of FVIII product and its Immunogenicity
Table 1
General determinants and modifiers of haemophilic bleeding phenotypes.
Determinant/modifier Basic pathophysiology Predictable effect on bleeding phenotype
FVIII gene mutation (a) Null mutations: Lack of FVIII production
(b) Non-null mutations: Reduced production of FVIII
(a) Null mutations: severe
haemophilia
(b) Non-null mutations: non-severe
haemophilia
Treatment Related Complications (a) FVIII Inhibitor: Neutralization of FVIII
(b) Viral Chronic Liver Disease: Multiple Coagulation Factor deficiency
(c) HIV: Thrombocytopenia
Higher Risk of all types of bleeding
FV-Leiden G1691A mutation Reduced inactivation of FVa-Leiden by Protein-C: Enhanced PROTHOMBINASE
activity with greater thrombin generation
Lower Risk of all types of bleeding
Protein-C gene mutation (Protein-C
deficiency)
Reduced inactivation of FVa and FVIIIa: Enhanced PROTHOMBINASE and TENASE
activity with greater thrombin generation.
Lower Risk of all types of bleeding
Protein-S gene mutation (Protein-S
deficiency)
Reduced inactivation of FVa and FVIIIa: Enhanced PROTHOMBINASE and TENASE
activity with greater thrombin generation.
Lower Risk of all types of bleeding
Antithrombin-III gene mutation
(Antithrombin-III deficiency)
Reduced inactivation of thrombin: Enhanced thrombin generation. Lower Risk of all types of bleeding
Prothrombin G20210A mutation Hyper-prothrombinemia: Enhanced thrombin generation Lower Risk of all types of bleeding
Methylenetetrahydrofolate reductase
gene C677T mutation
Hyper-homocysteinemia: Global activation of coagulation pathways Lower Risk of all types of bleeding
PAI-1 mutation Decreased Plasminogen Activation: Hypo-fibrinolysis with decreased fibrin
degradation
Lower Risk of all types of bleeding
ABO Blood Group Genes (a) Non-O Blood Group: Higher vWF levels with higher baseline FVIII level.
(b) Blood Group-O: Lower vWF levels with lower baseline FVIII level.
(a) Non-O Blood Group: Lower risk
of all types of bleeding
(b) Blood Group-O: Higher risk of all
types of bleeding
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of several other genetic factors that can potentially aggravate or
ameliorate the bleeding tendency as outlined in the subsequent
sections of this review.
2.2. Treatment related complications
Because haemophilia is a lifelong bleeding diathesis, patients
are repeatedly exposed to blood and blood products. Consequently,
patients may be further burdened with immunological and infec-
tive complications of product transfusion, which may include the
development of FVIII inhibitor and the acquisition of transfusion
transmissible infections such hepatitis and HIV.
2.2.1. Immunological complication: FVIII inhibitors
The clinical significance of FVIII inhibitors is linked to their
ability to neutralize FVIII as a result of which affected patients have
increased risk, frequency and severity of bleeding, with a concomi-
tant sub-optimal response to factor replacement and a correspond-
ing increase in the demand for factor concentrate that ultimately
raises the intensity and cost of treatment [13]. The risk of develop-
ing FVIII Inhibitor is mainly related to the type of FVIII mutation
[11]. It has been demonstrated that FVIII gene mutations that are
associated with the absence of the gene product (null mutations)
confer higher risk for inhibitor development, while mutations that
are associated with the presence of the gene product (non-null
mutations), even at very low level, confer a lower risk for inhibitor
development [11]. Interestingly, the type of FVIII mutation also sig-
nificantly influences the therapeutic response to Immune tolerance
induction (ITI) [14]. It appears that there is an inverse correlation
between the risk of inhibitor development and success rate of ITI
[14]. This is because it has been demonstrated that FVIII mutations
that confer higher risk of inhibitor development were also signifi-
cantly associated with lower success rates of ITI therapy than that
seen in patients with lower-risk FVIII mutations [14]. Apart from
FVIII gene mutations, other genetic factors also contribute to the
risk of developing inhibitors (Table 2). These factors include a
positive family history of inhibitors, ethnicity, and certain poly-
morphisms in immune modulatory genes that may increase
(eg IL-10 and TNF-alpha) or decrease (eg CTLA-4) the risk of devel-oping inhibitor [11,15]. The relatively higher incidence of polymor-
phisms in the immune modulatory genes for IL-10 and TNF-alpha
may partly explain the higher risk of inhibitor development in
blacks and other non-Caucasian haemophiliacs [16]. Moreover,
the role of ethnicity and FVIII haplotype variation between donor
and recipient in the development of FVIII inhibitors has been stud-
ied among black haemophiliacs living in Caucasian communities
[17]. The study suggested that mismatched factor VIII replacement
therapy is a risk factor for the development of FVIII antibodies in
black patients receiving human FVIII derived from Caucasian
plasma or rFVIII derived from genetic template obtained from
Caucasian genomes [17]. Moreover, the ABO blood groups play
important roles in the risk of inhibitor development as the inheri-
tance of non-O blood groups appear to confer a higher relative risk
of developing FVIII inhibitor as detailed in subsequent section
(section A3b).
The observation of discordance in inhibitor risks among hemo-
philic monozygotic twins [18] suggest the existence of non-genetic
factors in the development of FVIII inhibitors (Table 2). It has been
suggested that exposure to FVIII in the presence of non-genetic
immune modulators such as active infections or vaccinations, as
well as tissue damage due to accidental or surgical trauma have
the potential to generate signals that would activate the antigen-
presenting cells and increase the risk of developing FVIII inhibitors
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first exposure to FVIII, type of FVIII product and its inherent
immunogenicity, as well as the intensity of treatment, especially
when administered by continuous infusion may significantly
increase the risk of inhibitor development [18,20,21].
2.2.2. Infective complications: viral hepatitis and HIV
Transfusion of blood or blood products is associated with the
risks of contracting blood born infections such as hepatitis (B and
C) and HIV. The risks of acquiring these infections in the developed
countries have been greatly minimized as a result of moderniza-
tion of blood safety protocols with efficient donor screening proce-
dures, effective viral inactivation techniques and production of
recombinant blood products [22]. However, infection risks are par-
ticularly high in the tropics where the prevalence of blood born
infections is high, donor screening procedures are inadequate, viral
inactivation techniques are virtually absent, and recombinant
blood products are unavailable [23]. Both chronic viral hepatitis
and HIV infections can negatively affect the bleeding rates and
clinical phenotypes of infected haemophiliacs by causing chronic
liver disease with multiple coagulation factor deficiencies [24]
and HIV-associated thrombocytopenia [25]. In view of their pro-
thrombotic side effects, HIV protease inhibitors [26] may be partic-
ularly advantageous for HIV-infected haemophiliacs. This is
because the protease inhibitors will certainly treat the HIV infec-
tion and also predictably reduce the haemophilic bleeding rate as
a paradoxical ‘benefit’ of their prothrombotic side effects [26].
Hence, physicians involved in the management of HIV infections
may consider taking this point into perspective when ‘tailoring’
drug regimen for HIV-infected haemophiliacs especially for cases
that are complicated by thrombocytopenia.
2.3. Coinheritance of thrombophilia genes
Coinheritance of a number of prothrombotic gene mutations
resulting in milder bleeding phenotypes in severe haemophiliacs
have been described. These mutations include a wide spectrum
of genetic polymorphisms, including classical thrombophilias such
as the FV-Leiden G1691A, Protein-C, Protein-S, Antithrombin-III,
Prothrombin G20210A, Methylenetetrahydrofolate reductase
(MTHFR) C677T and Plasminogen Activator Inhibitor-1 (PAI-1)
mutations, as well as the non-classical thrombophilias such as
the non-O blood groups [11].
2.3.1. Coinheritance of classical thrombophilia
From pathophysiologic perspectives, coinheritance of
thrombophilic genes would modify the haemophilic thrombo-
haemorrhagic balance by reducing bleeding tendencies and
positively influencing the phenotypic expression of haemophilia. A
classical example of this scenario is the coinheritance of FV-Leiden
mutation. Under normal physiological conditions, the intrinsic anti-
coagulant Protein-C pathway (encompassing Protein-C, Protein-S
and Thrombomodulin) inactivates excess FVa and FVIIIa in order
to maintain a normal thrombo-haemorrhagic balance [27]. How-
ever, the mutant FVa-Leiden is resistant to inactivation by the
Protein-C pathway [28]. Hence, coinheritance of FV-Leiden with
haemophilia leads to relatively high FVa-Leiden activity, which
enhances the prothrombinase complex, and subsequently shifts
the thrombo-haemorrhagic balance in favour of greater thrombin
generationwith a significant reduction in bleeding rates [28]. More-
over, it should be appreciated thatmutations that affect any compo-
nent (eg Protein-C or protein-S deficiency) of the intrinsic
anticoagulant Protein-C pathway would lead to impaired inactiva-
tion of even normal FVa and FVIIIa [27]. Consequently, such muta-
tions (eg Protein-C or protein-S deficiency) enhance both the
tenase and prothrombinase complexes, which would subsequentlyincrease thrombin generation and predictably reduce bleeding rates
in haemophiliacs [29,30]. Animal haemostatic model suggests that
Antithrombin-III deficiency mutation, which causes reduction in
thrombin neutralization, is also associated with lower haemophilic
bleeding rates [31]. Other thrombophilic mutations that are associ-
ated with increase in thrombin generation (eg prothrombin
G20210Amutation), decrease in fibrin degradation (eg PAI-1 muta-
tion) or global increase in activation of coagulation pathways (eg
MTHFR C677T mutation) would also reduce bleeding rates in hae-
mophilia patients [32].2.3.2. Coinheritance of non-classical thrombophilia: non-O blood
groups
The ABO-related differences in glycosylation patterns of vWF
strongly influence its clearance. Consequently, vWF levels are
25–30% higher in non-O plasma than in group-O plasma [33].
The high levels of vWF in non-O plasma are linearly correlated
with parallel elevations of FVIII levels [34] due to the physiological
role of vWF as the carrier of FVIII and its protector from proteolysis
[35]. These normal variations in vWF and FVIII levels between ABO
groups are of triple clinical significance. First, higher levels of vWF
enhance platelet adhesion in the primary haemostatic pathway
leading to faster platelet aggregation [36] and shorter bleeding
time [37] in normal persons with non-O blood groups. Second,
higher levels of FVIII level enhance the tenase complex in the sec-
ondary haemostatic pathway leading to faster generation of fibrin
thrombi [38] and shorter clotting time [37] in normal persons with
non-O blood groups. Third, a meta-analysis had revealed that the
non-O blood type is the commonest genetic risk factor for venous
thromboembolism [39], which implies that the non-O blood group
is a genetic marker of thrombophilia (albeit non-classical). These
strong linkages between ABO blood groups and haemostasis in
normal (non-haemophilic) persons underscore the potential signif-
icance of the ABO blood groups as modifiers of haemophilic bleed-
ing phenotypes. It is therefore not surprising that ABO blood
groups have been shown to contribute to the inter-individual vari-
ations in the half-life of infused FVIII [40] and its in vivo immuno-
genicity [41] in recipient haemophiliacs. For example, it has been
demonstrated that in comparison to haemophiliacs with non-O
blood group, haemophiliacs with blood group-O have lower vWF
antigen level with corresponding lower half-life of infused FVIII
and a commensurate higher annual clotting factor consumption
[40,42], which imply higher bleeding rates. Moreover, haemophil-
iacs with blood group-O had higher risk of peri-operative
bleeding despite factor supplementation [43]. In contradistinction
to the aforementioned disadvantages of blood group-O, a recent
study revealed that blood group-O appears to be a negative regula-
tor of in vivo immunogenicity of infused FVIII and hence a protec-
tor against the development of inhibitors, a finding that is
potentially highly advantageous for haemophiliacs with blood
group-O [41].3. Tropical determinants and modifiers of haemophilic bleeding
phenotypes
The tropical environment is characterized by certain geograph-
ical, microbiological and socio-economic peculiarities that influ-
ence the pattern of genetic mutations and infectious diseases.
However, the vast majority of the literature on haemophilia origi-
nate from the developed temperate countries devoid of these pecu-
liarities. Consequently, the impact of tropical modifiers on clinical
phenotypes of haemophilia are not adequately investigated and
documented. Nonetheless, it is pertinent to study and understand
the mechanisms by which some prothrombotic tropical gene
mutations (such as the sickle b-globin gene mutation) and certain
Table 3
Tropical Determinants and Modifiers of Bleeding Phenotypes in Haemophiliacs.
Determinant/modifier Basic pathophysiology Predictable effect on bleeding phenotype
HbS Gene Mutation (SCT and SCD) Sickle cell associated hypercoagulability due to red cell sickling, release of membrane
phospholipids and increased monocyte-tissue factor expression
Lower Risk of all types of bleeding
Helminthic Infection of
Gastrointestinal Tract
Parasite-induced mucosal injury with or without parasite-associated anticoagulant
production (e.g. ancylostomal anti-FX and anti-FXI production)
Higher Risk of Gastrointestinal
Tract Bleeding
Urinary Schistosomiasis Parasite-induced mucosal injury and parasite-associated anticoagulant
production (S. haematobium anti-thrombin production)
Higher Risk of Urinary
Tract Bleeding
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urinary and gastrointestinal helminthiasis) may modify the fre-
quency, intensity and pattern of bleeding among haemophiliacs
living in the tropics as outlined in Table 3.
3.1. Tropical prothrombotic mutation: HbS gene mutation
Haemoglobin S (HbS) is a structural variant of the normal hae-
moglobin (HbA) [44]. HbS arose as a result of a genetic mutation in
the b globin gene where thymidine replaced adenine resulting in
the substitution of glutamic acid by valine in position-6 of the b
globin chain [44]. This sickle b-gene mutation confers relative pro-
tection against falciparum malaria among individuals who inher-
ited the sickle cell trait (SCT) [45]. Therefore, natural selection by
malaria is the single most important driver for the perpetuation
and high prevalence of SCT, which subsequently leads to high rates
of inter-marriages with significant incidence of sickle cell disease
(SCD) in black Africa and other tropical regions of the world [46].
For example, Nigeria has the largest back population of over 170
m with SCT prevalence of 25–30% and SCD prevalence 1–3% [47].
Hence, Nigeria is thought to carry the heaviest burden of SCD in
the world [47]. Both SCT and SCD are strongly associated with
increased risks of venous thrombo-embolism [48,49] due to the
combined hypercoagulable effects of red cell sickling [50] with
resultant scrambling and asymmetry of red cell membrane phos-
pholipids [51] and the release of procoagulant red cell membrane
phospholipids [52]. Moreover, both SCT and SCD are associated
with relative elevation of monocyte count with increased
expression of monocyte-derived tissue factor [50], which is
thought to aggravate the prothrombotic hypercoagulability due
to the aforementioned red cell sickling-induced membrane phos-
pholipid changes [50–52]. These studies [48–52] strongly suggest
that the sickling disorders are essentially thrombophilic. Hence,
coinheritance of the either SCT or SCD should predictably amelio-
rate haemophilic bleeding phenotypes. However, research in this
area is very scanty and probably consists of only two reports in
the literature at the moment. The first study is a case report from
India, which revealed lower incidence of bleeding complications
in a patient with coinheritance of severe haemophilia-A and SCD
[53]. The second study is a small retrospective study from Nigeria,
which revealed lower frequencies of spontaneous bleeding in
patients with coinheritance of severe haemophilia-A and SCT
[54]. These two studies preliminarily suggest that SCT and SCD
are positive modifiers of bleeding phenotypes in haemophiliacs.
However, more research is needed in this area of study.
3.2. Tropical pro-haemorrhagic parasitic infections: intestinal and
urinary helminths
Developing tropical countries are often associated with low
resources, poor environmental sanitation and high prevalence of
intestinal helminths, which contribute to high incidence of iron
deficiency within the local populations, especially among children
[55]. Intestinal helminths cause iron deficiency by inducing malab-
sorption and gastrointestinal haemorrhage (GIH) even in haemo-statically normal persons [55]. Intestinal helminths may cause
GIH by inducing mucosal injuries leading to a wide spectrum of
chronic or intermittent blood losses that range from occult bleed-
ing to melena and frank bleeding on the one hand, and from upper
to lower gastrointestinal bleeding episodes on the other hand
[56–60]. In addition to mucosal injuries, some intestinal helminths
have the capacity to manipulate the host haemostatic system by
actively producing anti-coagulants such as anti- FX and anti-FIX
in the case of hook worms [61]. Therefore, intestinal helminthiasis
is an important risk factor for GIH even in haemostatically normal
individuals. Hence, it is easy to infer that the haemostatic abnor-
mality associated with haemophilia would create a highly pro-
haemorrhagic host-parasite relationship, which would make the
haemophiliacs particularly vulnerable to the haemorrhagic effects
of intestinal helminths. However, this potentially significant vul-
nerability have not been adequately studied because the vast
majority of publications on haemophilia arose from developed
nations where parasitic diseases are not prevalent. A single study
conducted in Nigeria on the subject matter revealed that
haemophiliacs with intestinal helminthiasis had significantly
higher frequency of GIH and iron deficiency than their counter-
parts without helminthiasis [62]. This solitary study preliminarily
suggests that intestinal helminthiasis is a negative modifier of
gastrointestinal bleeding rate and phenotype in infected
haemophiliacs. Therefore, healthcare givers in the tropics
should ensure that all haemophiliacs are regularly screened and
de-wormed as appropriate.
Urinary schistosomiasis, caused by Schistosoma haematobium, is
yet another tropical pro-haemorrhagic parasitic disease. The adult
Schistosoma haematobium parasites preferentially settle in the
vesical plexus wherein they reproduce and produce eggs. Oviposi-
tion by the adult female parasites is characterized by continuing
egg deposition in the vesical sub-mucosa leading to extensive
inflammation, epithelial damage and haematuria [63]. In addition
to epithelial injuries, S. haematobium parasite is known to secrete
serine protease inhibitors with anti-thrombin properties that
manipulate the host haemostatic system and escalate the severity
of the haematuria [64]. Consequently, urinary schistosomiasis is an
important cause of haematuria and iron deficiency even in
haemostatically normal persons in the tropics [65]. It can therefore
be easily deduced that the haemostatic abnormality associated
with haemophilia would create a highly pro-haemorrhagic host-
parasite relationship, which would make the haemophiliacs partic-
ularly vulnerable to the haemorrhagic effects of urinary schistoso-
miasis. In similarity with intestinal helminthiasis, the significance
of urinary schistosomiasis is not adequately studied because the
vast majority of publications on haemophilia originated from
developed countries in which parasitic diseases are not prevalent.
However, a solitary study from Nigeria found out that although
haematuria is not uncommon in haemophiliacs, it is mainly caused
by spontaneous haemorrhage or trauma (blunt abdominal trauma)
while schistosomiasis was responsible for about 20% of cases [66].
Moreover, the study revealed that schistosomal haematuria was
severer and caused significant anaemia in contradistinction to
spontaneous and traumatic haematuria that were milder and did
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study suggest that urinary schistosomiasis is a potential negative
modifier of frequency and severity of urinary tract bleeding in
haemophiliacs infected by the parasite. Therefore, healthcare
givers in the tropics should ensure that all haemophiliacs present-
ing with haematuria in schistosomiasis endemic countries should
be properly investigated by urinalysis for early detection and treat-
ment. In particular, haemophiliacs who present with haematuria in
association with eosinophilia should evoke the strongest clinical
suspicion for urinary schistosomiasis [66].
3.3. Tropical pro-haemorrhagic parasitic infections: iron deficiency
and its clinical implications for the haemophilia patient
The combined effect of poverty, malnutrition and frequent
bleeding are sufficient to cause anaemia among haemophiliacs in
the tropics [12]. Moreover, the acquisition of any tropical pro-
haemorrhagic infections, especially the soil-transmitted helminths
and schistosomiasis, which are notorious for causing blood loss
and iron deficiency even in haemostatically normal persons [67],
would considerably increase the risks of blood loss and iron defi-
ciency among haemophiliacs living in tropical countries [62,66].
It is intriguing to note that iron deficiency is a potentially pro-
thrombotic state as it is associated with increased blood viscosity
[68] and thrombocytosis [69], and is thus reported to be an impor-
tant risk factor for venous thromboembolism in haemostatically
normal persons [70]. For the aforementioned reasons, iron defi-
ciency may predictably reduce bleeding rates in haemophiliacs.
However, this potential benefit is outweighed by a myriad of
potentially adverse effects of iron deficiency that are highly
undesirable in the haemophiliac viz cognitive retardation [71],
impairment of wound healing [72] and immune dysfunction
[73]. It is therefore highly desirable that even the mildest
iron deficiency must be treated with vigor especially in the
school-age haemophilic children in whom it may cause cognitive
dysfunction with poor intellectual performance, as well as
predispose to wound infection and delayed wound healing that
would result in undue school absenteeism. Nonetheless, there are
important challenges in the treatment of iron deficiency in the
setting of haemophilia.
The major therapeutic challenges arise from the fact that one of
the side effects of iron therapy is erosive gastritis, which is com-
monly associated with iron pills, but not with liquid iron prepara-
tions [74]. Erosive gastritis can increase the risk of gastric bleeding,
which is not uncommon in haemophiliacs, especially in those
infected by Helicobacter pylori [75]. The risk of iron-induced erosive
gastritis would be higher in iron-deficient older children and adult
haemophiliacs as these age groups are more likely to be treated
with iron pills rather than liquid iron preparations. Therefore,
haemophiliacs taking iron pills must be closely monitored for clin-
ical features of gastritis and bleeding such as epigastric pain and
passage of melena stool [76]. However, the dilemma in this per-
spective is the fact that iron preparations may by themselves also
cause blackish discoloration of the stool (in the absence of any
bleeding), which may be physically and chemically indistinguish-
able from true melena [77]. In view of these eventualities, we rec-
ommend that iron-deficient haemophiliacs, irrespective of their
ages, should preferably be treated with liquid iron preparations
as they are less toxic to the gastrointestinal tract [74]. Iron
deficient haemophiliacs who develop intolerable gastritis and/or
gastric bleeding due to oral iron may be cautiously treated with
intravenous preparation under close supervision in view of the
possible risks of anaphylaxis [78] and extravasation, which can
cause localized inflammation, skin pigmentation and sensory
deficit [79]. Nonetheless, we believe that the safest and the most
convenient way of treating iron deficiency in haemophiliacs is byoptimal dietary supplementation with iron-rich food items such
as liver and red meat in conjunction with iron-fortified cereal-
based meals, all of which are devoid of the side effects of conven-
tional pharmaceutical iron preparations [80].
4. Conclusion
Disease severity as determined by the extent to which different
mutations abolish FVIII production remains the most important
determinant of haemophilic bleeding phenotypes. However, the
overall phenotypic variation among haemophiliacs is determined
by the interactions between the haemophilic pathophysiologic
processes and effect of several other factors, which range from
general to tropical factors on the one hand, and genetic to
immunologic and infective factors on the other hand. While the
roles of classical thrombophilias such as FV-Leiden is fairly well
established within the context of clinical phenotyping of
haemophiliacs, there is the need for more research to elucidate
the clinical significance of non-classical thrombophilias such as
the non-O blood groups and the sickle b-globin gene mutation,
and also to further investigate the diametrically opposed roles of
blood group-O, which is associated with relative increase in bleed-
ing rates on the one hands, and a protector against development of
FVIII inhibitor on the other hand. It is pertinent to screen every
haemophiliac for the presence of co-existing bleeding modifiers
at the time of diagnosis in order to predict individual patient prog-
nosis and clotting factor requirement. Meanwhile, healthcare
workers in the tropics should incorporate mandatory and regular
screening and treatment for common pro-haemorrhagic parasitic
diseases and iron deficiency into the standard of care for the
management of haemophilia patients living in the tropical
environment.
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